64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. / Carlsen, Esben Andreas; Johnbeck, Camilla Bardram; Binderup, Tina; Loft, Mathias; Pfeifer, Andreas; Mortensen, Jann; Oturai, Peter; Loft, Annika; Berthelsen, Anne Kiil; Langer, Seppo W.; Knigge, Ulrich; Kjaer, Andreas.

In: The Journal of Nuclear Medicine, Vol. 61, No. 10, 2020, p. 1491-1497.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Carlsen, EA, Johnbeck, CB, Binderup, T, Loft, M, Pfeifer, A, Mortensen, J, Oturai, P, Loft, A, Berthelsen, AK, Langer, SW, Knigge, U & Kjaer, A 2020, '64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms', The Journal of Nuclear Medicine, vol. 61, no. 10, pp. 1491-1497. https://doi.org/10.2967/jnumed.119.240143

APA

Carlsen, E. A., Johnbeck, C. B., Binderup, T., Loft, M., Pfeifer, A., Mortensen, J., ... Kjaer, A. (2020). 64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. The Journal of Nuclear Medicine, 61(10), 1491-1497. https://doi.org/10.2967/jnumed.119.240143

Vancouver

Carlsen EA, Johnbeck CB, Binderup T, Loft M, Pfeifer A, Mortensen J et al. 64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. The Journal of Nuclear Medicine. 2020;61(10):1491-1497. https://doi.org/10.2967/jnumed.119.240143

Author

Carlsen, Esben Andreas ; Johnbeck, Camilla Bardram ; Binderup, Tina ; Loft, Mathias ; Pfeifer, Andreas ; Mortensen, Jann ; Oturai, Peter ; Loft, Annika ; Berthelsen, Anne Kiil ; Langer, Seppo W. ; Knigge, Ulrich ; Kjaer, Andreas. / 64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. In: The Journal of Nuclear Medicine. 2020 ; Vol. 61, No. 10. pp. 1491-1497.

Bibtex

@article{e42e41b4b41543c8baf2c003c3458efc,
title = "64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms",
abstract = "Overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) is utilized for both diagnosis and treatment. Receptor density may reflect tumor differentiation and thus be associated with prognosis. Non-invasive visualization and quantification of somatostatin receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET). Recently, we introduced 64Cu-DOTATATE for SRI and we hypothesized that uptake of this tracer could be associated with overall (OS) and progression-free survival (PFS). Methods: We evaluated patients with NEN that had a 64Cu-DOTATATE PET/CT SRI performed in two prospective studies. Tracer uptake was determined as the maximal standardized uptake value (SUVmax) for each patient. Kaplan-Meier analysis with log-rank was used to determine the predictive value of 64Cu-DOTATATE SUVmax for OS and PFS. Specificity, sensitivity and accuracy was calculated for prediction of outcome at 24 months after 64Cu-DOTATATE PET/CT. Results: A total of 128 patients with NEN were included and followed for a median of 73 (1-112) months. During follow-up, 112 experienced disease progression and 69 patients died. The optimal cutoff for 64Cu-DOTATATE SUVmax was 43.3 for prediction of PFS with a hazard ratio of 0.56 (95{\%} CI: 0.38-0.84) for patients with SUVmax > 43.3. However, no significant cutoff was found for prediction of OS. In multiple Cox regression adjusted for age, sex, primary tumor site and tumor grade, the SUVmax cutoff hazard ratio was 0.50 (0.32-0.77) for PFS. The accuracy was moderate for predicting PFS (57{\%}) at 24 months after 64Cu-DOTATATE PET/CT. Conclusion: In this first study to report the association of 64Cu-DOTATATE PET/CT and outcome in patients with NEN, tumor somatostatin receptor density visualized with 64Cu-DOTATATE PET/CT was prognostic for PFS but not OS. However, the accuracy of prediction of PFS at 24 months after 64Cu-DOTATATE PET/CT SRI was moderate limiting the value on an individual patient basis.",
author = "Carlsen, {Esben Andreas} and Johnbeck, {Camilla Bardram} and Tina Binderup and Mathias Loft and Andreas Pfeifer and Jann Mortensen and Peter Oturai and Annika Loft and Berthelsen, {Anne Kiil} and Langer, {Seppo W.} and Ulrich Knigge and Andreas Kjaer",
note = "Copyright {\circledC} 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2020",
doi = "10.2967/jnumed.119.240143",
language = "English",
volume = "61",
pages = "1491--1497",
journal = "The Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "10",

}

RIS

TY - JOUR

T1 - 64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms

AU - Carlsen, Esben Andreas

AU - Johnbeck, Camilla Bardram

AU - Binderup, Tina

AU - Loft, Mathias

AU - Pfeifer, Andreas

AU - Mortensen, Jann

AU - Oturai, Peter

AU - Loft, Annika

AU - Berthelsen, Anne Kiil

AU - Langer, Seppo W.

AU - Knigge, Ulrich

AU - Kjaer, Andreas

N1 - Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2020

Y1 - 2020

N2 - Overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) is utilized for both diagnosis and treatment. Receptor density may reflect tumor differentiation and thus be associated with prognosis. Non-invasive visualization and quantification of somatostatin receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET). Recently, we introduced 64Cu-DOTATATE for SRI and we hypothesized that uptake of this tracer could be associated with overall (OS) and progression-free survival (PFS). Methods: We evaluated patients with NEN that had a 64Cu-DOTATATE PET/CT SRI performed in two prospective studies. Tracer uptake was determined as the maximal standardized uptake value (SUVmax) for each patient. Kaplan-Meier analysis with log-rank was used to determine the predictive value of 64Cu-DOTATATE SUVmax for OS and PFS. Specificity, sensitivity and accuracy was calculated for prediction of outcome at 24 months after 64Cu-DOTATATE PET/CT. Results: A total of 128 patients with NEN were included and followed for a median of 73 (1-112) months. During follow-up, 112 experienced disease progression and 69 patients died. The optimal cutoff for 64Cu-DOTATATE SUVmax was 43.3 for prediction of PFS with a hazard ratio of 0.56 (95% CI: 0.38-0.84) for patients with SUVmax > 43.3. However, no significant cutoff was found for prediction of OS. In multiple Cox regression adjusted for age, sex, primary tumor site and tumor grade, the SUVmax cutoff hazard ratio was 0.50 (0.32-0.77) for PFS. The accuracy was moderate for predicting PFS (57%) at 24 months after 64Cu-DOTATATE PET/CT. Conclusion: In this first study to report the association of 64Cu-DOTATATE PET/CT and outcome in patients with NEN, tumor somatostatin receptor density visualized with 64Cu-DOTATATE PET/CT was prognostic for PFS but not OS. However, the accuracy of prediction of PFS at 24 months after 64Cu-DOTATATE PET/CT SRI was moderate limiting the value on an individual patient basis.

AB - Overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) is utilized for both diagnosis and treatment. Receptor density may reflect tumor differentiation and thus be associated with prognosis. Non-invasive visualization and quantification of somatostatin receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET). Recently, we introduced 64Cu-DOTATATE for SRI and we hypothesized that uptake of this tracer could be associated with overall (OS) and progression-free survival (PFS). Methods: We evaluated patients with NEN that had a 64Cu-DOTATATE PET/CT SRI performed in two prospective studies. Tracer uptake was determined as the maximal standardized uptake value (SUVmax) for each patient. Kaplan-Meier analysis with log-rank was used to determine the predictive value of 64Cu-DOTATATE SUVmax for OS and PFS. Specificity, sensitivity and accuracy was calculated for prediction of outcome at 24 months after 64Cu-DOTATATE PET/CT. Results: A total of 128 patients with NEN were included and followed for a median of 73 (1-112) months. During follow-up, 112 experienced disease progression and 69 patients died. The optimal cutoff for 64Cu-DOTATATE SUVmax was 43.3 for prediction of PFS with a hazard ratio of 0.56 (95% CI: 0.38-0.84) for patients with SUVmax > 43.3. However, no significant cutoff was found for prediction of OS. In multiple Cox regression adjusted for age, sex, primary tumor site and tumor grade, the SUVmax cutoff hazard ratio was 0.50 (0.32-0.77) for PFS. The accuracy was moderate for predicting PFS (57%) at 24 months after 64Cu-DOTATATE PET/CT. Conclusion: In this first study to report the association of 64Cu-DOTATATE PET/CT and outcome in patients with NEN, tumor somatostatin receptor density visualized with 64Cu-DOTATATE PET/CT was prognostic for PFS but not OS. However, the accuracy of prediction of PFS at 24 months after 64Cu-DOTATATE PET/CT SRI was moderate limiting the value on an individual patient basis.

U2 - 10.2967/jnumed.119.240143

DO - 10.2967/jnumed.119.240143

M3 - Journal article

C2 - 32111685

VL - 61

SP - 1491

EP - 1497

JO - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -

ID: 247890395